Development of CAR-T cell based on a newly identified tumor antigen
MJ Cellbio – Beyond New Horizon
Pipeline
| Pipeline | R&D Stage | Characteristics | ||
| Basic research | Preclinical research | Phase I~III | ||
| PA-CAR-T |
 |
|
||
| Cy- / Home-CAR-T |  |
Development of CAR with cytokine or chemokine receptor to enhance function and/or localization | ||
| Uni CAR-T | |
Development of off-the-shelf CAR-T cells using genome editing | ||
| NK cell | |
Development of therapy by using NK cells active even in tumor microenvironment (hypoxia) | ||
| ETC | |
Development of immunotherapy using combination of Neo-antigen and tumor associated antigen peptides | ||
| ROP T CELL | |
Development of antigen-specific T-cell therapy using ROP (recombinant overlapping peptide) of Oxford Vacmedix | ||
Pipeline Development of MJCELLBIO
CAR-T Therapy Is Now Realized and Getting Competitive
